The primary objectives of this study are to assess the efficacy of levetiracetam XR in
increasing the percentage of subjects with no heavy drinking days and in reducing the weekly
percentage of heavy drinking days in subjects with alcohol dependence confirmed by DSM-IV
criteria and who frequently consume 10 or more drinks per drinking day for men and 8 or more
drinks per drinking day for women (designated as "very heavy" drinkers).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)